Table 2 Outcomes of the clinical trials included in the meta-analysis
Study | Sample size (n) | HCV genotype (n) | End of treatment | End of follow-up | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HCV ETVR (n) | ALT normalization (n) | HCV SVR (n) | HCV relapse (n) | ALT normalization (n) | ||||||||||
Genotype 1 | Non- genotype 1 | Overall | Genotype 1 | Non-genotype 1 | Overall | Genotype 1 | Non-genotype 1 | Overall | Genotype 1 | Non-genotype 1 | ||||
Yu et al. [35] | C: 50 | 30 | 20 | 46 | 27 | 19 | NR | 27 | 12 | 15 | 19 | 15 | 4 | NR |
M: 46 | 25 | 21 | 32 | 14 | 18 | NR | 26 | 11 | 15 | 6 | 3 | 3 | NR | |
Liu et al. [32] | C: 161 | 97 | 64 | 138 | 82 | 56 | NR | 123 | 70 | 53 | 15 | 12 | 3 | 103 |
M: 160 | 110 | 50 | 141 | 95 | 46 | NR | 127 | 85 | 42 | 14 | 10 | 4 | 122 | |
Chuang et al. [34] | C: 42 | 21 | 21 | NR | NR | NR | NR | 29 | 10 | 19 | NR | NR | NR | 23 |
M: 84 | 48 | 36 | NR | NR | NR | NR | 54 | 39 | 15 | NR | NR | NR | 51 | |
Hung et al. [30] | C: 36 | 17 | 19 | 33 | NR | NR | 24 | 25 | 10 | 15 | 8 | NR | NR | 20 |
M: 72 | 34 | 38 | 68 | NR | NR | 66 | 51 | 18 | 33 | 17 | NR | NR | 52 | |
Liu et al. [36] | C: 24 | 14 | 7 | 16 | 10 | 6 | 12 | 9 | 3 | 6 | 7 | NR | NR | 9 |
M: 30 | 17 | 13 | 25 | NR | NR | 23 | 18 | NR | NR | 5 | NR | NR | 18 | |